Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇳🇿NZ · Science#943K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
2.1K to 7K🎙 Biweekly cadence·9 episodes·Long inactive - Monthly Reach
Unique listeners across all episodes (30 days)
3K to 10K🇳🇿100% - Active Followers
Loyal subscribers who consistently listen
900 to 3K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (audio)
Apr 16, 2014
Unknown duration
Late Stage Oropharynx Cancer, Treatment and Side Effects (audio)
Mar 30, 2014
Unknown duration
Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (audio)
Mar 30, 2014
Unknown duration
Late Stage Oropharynx Cancer, Introduction and Management (audio)
Mar 30, 2014
Unknown duration
Squamous Lung Cancer Part 5, Q and A Session (audio)
Dec 20, 2013
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4/16/14 |  Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (audio) | Dr. Jared Weiss, University of North Carolina, discusses chemotherapy options and practice in late stage oropharynx cancer. | — | ||||||
| 3/30/14 |  Late Stage Oropharynx Cancer, Treatment and Side Effects (audio) | Dr. Geoffrey Geiger, University of Pennsylvania, outlines the course of radiotherapy treatment and side effects for head and neck cancer. | — | ||||||
| 3/30/14 |  Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (audio) | Dr. Geoffrey Geiger, University of Pennsylvania, discusses the process of planning radiotherapy for head and neck cancer. | — | ||||||
| 3/30/14 |  Late Stage Oropharynx Cancer, Introduction and Management (audio) | Dr. Geoffrey Geiger, University of Pennsylvania, provides an introduction to head and neck cancer and the human papilloma virus. | — | ||||||
| 12/20/13 |  Squamous Lung Cancer Part 5, Q and A Session (audio) | Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer. | — | ||||||
| 12/10/13 |  Squamous Lung Cancer, Part 4: Immunotherapy (audio) | Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer. | — | ||||||
| 12/8/13 |  Squamous Lung Cancer, Part 3: Treatment (audio) | Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer. | — | ||||||
| 12/6/13 |  Squamous Lung Cancer, Part 2: Genomic Testing (audio) | Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer. | — | ||||||
| 12/2/13 |  Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio) | Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer. | — | ||||||
| 9/28/13 |  Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (audio) | Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 9/28/13 |  Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (audio) | Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer. | — | ||||||
| 9/21/13 |  Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (audio) | Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer. | — | ||||||
| 9/19/13 |  Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (audio) | Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer. | — | ||||||
| 9/9/13 |  Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (audio) | Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer. | — | ||||||
| 9/4/13 |  ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio) | Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC. | — | ||||||
| 8/31/13 |  ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio) | Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma. | — | ||||||
| 8/26/13 |  ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio) | Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma. | — | ||||||
| 8/26/13 |  ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio) | Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC. | — | ||||||
| 8/23/13 |  ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio) | Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC. | — | ||||||
| 8/23/13 |  ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio) | Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC. | — | ||||||
| 8/16/13 |  ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio) | Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC. | — | ||||||
| 8/16/13 |  ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio) | Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer. | — | ||||||
| 8/15/13 |  ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio) | Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials. | — | ||||||
| 8/14/13 |  Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (audio) | Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with the molecular biology of pancreatic cancer. | — | ||||||
| 8/14/13 |  ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio) | Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC. | — | ||||||
Showing 25 of 48
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.